(@bavtad)

Goal 2: Reduce Human Disease

Bicuspid aortic valve is not a “one size fits all” condition. Variations exist within families and the population generally.

Clinical disease manifestations in individuals and families where bicuspid aortic valve is present may best be described as a spectrum, with considerable variability in presentation. Patients and families would benefit from an individualized approach, which does include familial medical history, but couples that information with current best understanding of BAV, considering both variations and risks.

Voting

-4 net votes
10 up votes
14 down votes
Active
(@jgrima)

Goal 3: Advance Translational Research

How can we determine a patient’s risk of a life-threatening aortic dissection?

Even though science and technology has advanced, many of the advancements have not met the critical challenge of making significant changes in patient therapies for improved outcomes and thus have not been able to break through the translational barrier. In today’s world, risk of aortic dissection is still based purely on a crude size measurement. It is true that evidence indicates that aortic root aneurysm above 4.5 ...more »

Voting

4 net votes
6 up votes
2 down votes
Active
(@haslach)

Goal 2: Reduce Human Disease

Mechanics of aortic dissection

The mechanical events in the wall leading to aortic dissection are not well described because merely stating that cellular or biopolymer connections have weakened does not predict the path of the rupture through the media or the risk of rupture. Elucidate the mechanical role of substructures such as collagen fibers, elastin sheets, smooth muscle cells and interstitial fluid in the progression of dissection. Study in animal ...more »

Voting

7 net votes
17 up votes
10 down votes
Active
(@bavtad)

Goal 2: Reduce Human Disease

Recognition of bicuspid aortic valve's complexity, life threatening potential, and familial implications.

There is a persistent perception that bicuspid aortic valve (BAV), the most common congenital heart defect (estimated to occur in up to 6 million Americans), is a benign condition that may not require treatment until later in life, if at all. The implications for other blood relatives, although referenced in medical literature, may not be acknowledged. This notion, coupled with the inability to identify those most at ...more »

Voting

1 net vote
12 up votes
11 down votes
Active
(@serevill)

Goal 2: Reduce Human Disease

Does lowering circulating lipoprotein(a) levels influence cardiovascular outcomes?

A comprehensive research strategy and plan is needed to determine the most efficient, safe, cost-effective and widely applicable strategy to decrease circulating levels of lipoprotein(a) and to determine whether lowering circulating lipoprotein(a) levels will reduce the risk of developing cardiovascular disease such as a heart attack or a stroke as well as the progression of atherosclerosis or aortic stenosis.

Voting

235 net votes
297 up votes
62 down votes
Active
(@bavtad)

Goal 2: Reduce Human Disease

Controversies exist regarding thoracic aortic disease imaging

Controversies exist regarding aortic disease imaging (the aorta as well as the aortic valve, including characterization in the presence of a bicuspid aortic valve (BAV)). Many imaging approaches are optimized for evaluation of coronary artery disease rather than aortic disease. Without accurate characterization, the degree of disease progression may be under estimated, patient symptoms may be discounted, and those who ...more »

Voting

0 net votes
11 up votes
11 down votes
Active
(@jdhutcheson)

Goal 2: Reduce Human Disease

Discovering unique targets to treat and cure calcific aortic valve disease

Calcific aortic valve disease (CAVD) is a major contributor of cardiovascular morbidity and mortality. No therapeutic strategies currently exist to prevent or treat CAVD. The aortic valve represents a unique and highly dynamic tissue, and it is important to recognize that although CAVD shares many commonalities with atherosclerosis, traditional risk factors for atherosclerotic plaque development remain relatively poor ...more »

Voting

28 net votes
33 up votes
5 down votes
Active